(:FLXN)

Nov 19, 2021 08:40 am ET
Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management
Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the completion of its previously announced acquisition of Flexion Therapeutics, Inc....
Nov 02, 2021 06:35 pm ET
FLEXION THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN
NEW ORLEANS, Nov. 2, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Flexion Therapeutics, Inc. (NasdaqGM: FLXN) to Pacira BioSciences, Inc. (NasdaqGS: PCRX).  Under the terms of the proposed transaction, shareholders of Flexion will receive only $8.50 in cash and one non-tradable contingent value right (CVR) worth up to $8.00 per share in cash (assuming certain conditions are met) for each share of Flexion that they own. KSF is seeking to determine whether this
Nov 02, 2021 03:46 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ACBI, GTS, ADTN, COLB, DSPG, FLXN; Shareholders are Encouraged to Contact the Firm
NEW YORK, Nov. 2, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Nov 01, 2021 09:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, COLB, FTSI, FLXN; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Great Western Bancorp, Inc. (NYSE: GWB) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Oct 30, 2021 07:08 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flexion Therapeutics, Inc. - FLXN
NEW YORK, Oct. 30, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Flexion Therapeutics, Inc. ("FLXN" or the "Company") (FLXN) relating to its proposed acquisition by Pacira BioSciences, Inc. Under the terms of the agreement, FLXN shareholders will receive $8.50 in cash per share they own.
Oct 28, 2021 02:25 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the Firm
NEW YORK, Oct. 28, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Oct 21, 2021 08:07 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ESBK, FLXN, COLB, CXP; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Elmira Savings Bank (NASDAQ: ESBK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Oct 21, 2021 05:25 pm ET
Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Meredith Corporation, Aspen Technology, Flexion, and Columbia Banking System on behalf of Stockholders and Enc
Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Meredith Corporation (NYSE: MDP), Aspen Technology, Inc. (NASDAQ: AZPN) (“AspenTech”), Flexion Therapeutics, Inc. (NASDAQ:...
Oct 21, 2021 12:01 am ET
Lifshitz Law Firm, P.C. Announces Investigation of ADMS, ACBI, FLXN, and HBMD
Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ADMS to Supernus Pharmaceuticals, Inc. for $8.10 in cash per share of ADMS...
Oct 20, 2021 02:13 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FLXN, AZPN, COLB, LMRK; Shareholders are Encouraged to Contact the Firm
NEW YORK, Oct. 20, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Oct 19, 2021 01:50 pm ET
MERGER ALERT - ADMS, AZPN, and FLXN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 19, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 15, 2021 02:14 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, FLXN, ACBI, SQ; Shareholders are Encouraged to Contact the Firm
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Oct 15, 2021 09:00 am ET
Moore Kuehn Encourages MDP, DUNE, FLXN, and AZPN Investors to Contact Law Firm
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
Oct 14, 2021 02:35 pm ET
MERGER ALERT - ADMS, AZPN, and FLXN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 14, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 13, 2021 12:40 pm ET
FLEXION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FLXN and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Flexion Therapeutics, Inc. (NASDAQ: FLXN) breached their fiduciary duties or violated the...
Oct 12, 2021 02:07 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, FLXN, AZPN, CXP; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Oct 12, 2021 01:30 pm ET
MERGER ALERT - ADMS, AZPN, and FLXN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 12, 2021 12:25 pm ET
FLEXION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Flexion Therapeutics, Inc. (NasdaqGM: FLXN) to Pacira BioSciences, Inc. (NasdaqGS: PCRX). Under the terms of the proposed transaction, shareholders of Flexion will receive only $8.50 in cash and one non-tradable contingent value right (CVR) worth up to $8.00 per share in cash (assuming certain conditions are met) for each share of Flexion that they own. KSF is seeking to determine whether this consideration and the process that led to it are
Oct 12, 2021 12:00 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Flexion Therapeutics, Inc. Merger
Rigrodsky Law, P.A. announces that it is investigating Flexion Therapeutics, Inc. (“Flexion”) (NASDAQ GM: FLXN) regarding possible breaches of fiduciary duties and other violations of law related to Flexion’s agreement to be acquired by Pacira...
Oct 11, 2021 11:41 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Flexion Therapeutics, Inc.
NEW YORK, Oct. 11, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Flexion Therapeutics, Inc. ("Flexion" or the "Company") (NASDAQ: FLXN) in connection with the proposed acquisition of the Company by Pacira BioSciences, Inc. ("Pacira") (NASDAQ: PCRX).  Under the terms of the merger agreement, Pacira will commence a tender offer to acquire all outstanding shares of Flexion for a purchase price of $8.50 per share in cash, plus one non-tradeable contingent value right ("CVR"). The CVR will entitle Fl
Oct 11, 2021 04:26 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc.
NEW YORK, Oct. 11, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Flexion Therapeutics, Inc. (NASDAQ: FLXN) and its board of directors concerning the proposed acquisition of the company by Pacira BioSciences, Inc. (NASDAQ: PCRX). Stockholders will receive $8.50 and one contingent value right worth up to $8.00 for each share of Flexion Therapeutics stock that they hold. The transaction is expected to close in the fourth quarter of 2021.
Oct 11, 2021 01:50 pm ET
Shareholder Alert: Ademi LLP investigates whether Flexion Therapeutics, Inc. has obtained a Fair Price in its transaction with Pacira
MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Flexion (Nasdaq: FLXN), for possible breaches of fiduciary duty and other violations of law in its transaction with Pacira.
Oct 11, 2021 12:00 pm ET
Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Flexion Therapeutics, Inc. (NASDAQ: FLXN) to Pacira BioSciences, Inc. for $8.50 per share in cash plus one non-tradeable contingent value right worth up to $8.00 per share in cash is fair to Flexion shareholders.
Oct 11, 2021 08:30 am ET
Thinking about buying stock in Protagonist Therapeutics, Flexion Therapeutics, Avadel Pharmaceuticals, US Well Services, or Magnolia Oil & Gas?
NEW YORK, Oct. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTGX, FLXN, AVDL, USWS, and MGY.
Oct 11, 2021 08:07 am ET
(FLXN): Johnson Fistel Investigates Proposed Sale of Flexion; Are Shareholders Getting a Fair Deal?
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Flexion Therapeutics, Inc. (NYSE: FLXN) ("Flexion " or the "Company") breached their fiduciary duties in connection with the proposed...
Oct 11, 2021 07:00 am ET
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced a definitive agreement pursuant to which...
Oct 11, 2021 07:00 am ET
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced a definitive agreement pursuant to which...
Oct 01, 2021 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of...
Sep 08, 2021 04:30 pm ET
Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference...
Sep 03, 2021 09:00 am ET
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference. The virtual fireside...
Sep 02, 2021 07:30 am ET
Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based clinical practice...
Aug 25, 2021 07:30 am ET
Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301 in patients undergoing bunionectomy. FX301 is a novel formulation of a locally administered NaV1.7...
Aug 09, 2021 04:30 pm ET
Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) were published in Drugs in R&D. The...
Aug 04, 2021 04:01 pm ET
Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2021. “We are encouraged by the growth of ZILRETTA sales in the second quarter of 2021, and today we are...
Jul 29, 2021 04:15 pm ET
Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET. A live webcast of the conference...
Jul 12, 2021 04:30 pm ET
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexion’s audit committee. "I am...
Jul 02, 2021 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 20,440 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of...
Jun 14, 2021 04:30 pm ET
Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James Human Health Innovation Conference. The virtual...
Jun 09, 2021 04:15 pm ET
Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021. "Will brings an impressive combination of medical, clinical, regulatory...
Jun 04, 2021 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 8,510 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of...
Jun 02, 2021 04:30 pm ET
Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference. The...
May 13, 2021 04:30 pm ET
Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2021 Virtual Global Healthcare Conference. The...
May 12, 2021 04:01 pm ET
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2021. “The first quarter of 2021 was marked by solid ZILRETTA sales and important progress with both FX201 and...
May 07, 2021 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to eight new employees consisting of 18,200 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of...
May 05, 2021 04:30 pm ET
Flexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, May 12, 2021. A live webcast of the conference call can be accessed...
Apr 28, 2021 07:30 am ET
Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Flexion Therapeutics, Inc. (Nasdaq:FLXN) will present preliminary data from a Phase 1 single ascending dose (SAD) trial of FX201 at the 2021 American Society of Gene & Cell Therapy (ASGCT) annual meeting taking place virtually May 11-14, 2021. “We...
Apr 13, 2021 04:01 pm ET
Flexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net sales of approximately $24.6 million for the quarter ended March 31, 2021. “Overall, we were pleased...
Apr 08, 2021 04:30 pm ET
Flexion Therapeutics to Present at the Needham 20th Annual Virtual Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham 20th Annual Healthcare Conference. The virtual fireside chat...
Apr 02, 2021 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 60,880 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of...
Mar 31, 2021 07:30 am ET
Flexion Therapeutics Announces First Patient Treated in FX301 Phase 1b Trial for Management of Post-Operative Pain
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in a Phase 1b proof-of-concept trial evaluating the safety and tolerability of FX301 administered as a single-dose, popliteal fossa block (a commonly used...
Mar 15, 2021 09:00 am ET
Flexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference. The virtual fireside...
Mar 10, 2021 04:01 pm ET
Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter and the full year ended December 31, 2020. “Despite the unprecedented challenges presented by the global pandemic, 2020 was...
Mar 05, 2021 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of 14,565 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of...
Mar 03, 2021 04:30 pm ET
Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2020 Financial Results on March 10, 2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after the close of the U.S. financial markets on Wednesday, March 10, 2021. A live webcast of the conference call...
Mar 01, 2021 07:30 am ET
Flexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301, a Novel Formulation of a Locally Administered NaV1.7 Inhibitor for Post-Operative Pain
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for FX301, a locally administered NaV1.7 inhibitor known as funapide, formulated for...
Feb 22, 2021 04:30 pm ET
Flexion Therapeutics to Present at the 42nd Annual Raymond James Virtual Institutional Investors Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 42nd Annual Raymond James Institutional Investors Conference. The...
Feb 18, 2021 07:30 am ET
Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment Groups
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced plans to advance FX201 into the high dose cohort of the Phase 1 dose-escalation trial. The trial is evaluating the safety and tolerability of FX201, an investigational, intra-articular,...
Feb 01, 2021 09:00 am ET
National Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA®
The National Basketball Retired Players Association (NBRPA) and Flexion Therapeutics Inc. today announced a new partnership to raise awareness of osteoarthritis-related knee pain and present ZILRETTA (triamcinolone acetonide extended-release...
Jan 13, 2021 07:00 am ET
Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited net sales for the fourth quarter and full year ended December 31, 2020. “We are very pleased to report preliminary full-year 2020 ZILRETTA net sales of...
Jan 07, 2021 04:30 pm ET
Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the ICR | Westwicke Investment Conference. The virtual fireside chat is...
Dec 07, 2020 04:30 pm ET
Flexion Therapeutics to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics...
Dec 04, 2020 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of 22,798 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of...
Nov 06, 2020 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of...
Nov 05, 2020 04:30 pm ET
Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference. The virtual...
Nov 04, 2020 04:01 pm ET
Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30, 2020. “Throughout the third quarter, we saw strong execution across all areas of our business, and we were...
Oct 29, 2020 04:30 pm ET
Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 4, 2020. The company hosted a conference call on October 13,...
Oct 13, 2020 06:59 am ET
Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net sales of $23.6 million for the quarter ended September 30, 2020. “We are very pleased with our...
Oct 08, 2020 04:30 pm ET
Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual Meeting on the Mesa
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the annual 2020 Cell & Gene Virtual Meeting on the Mesa. Dr. Muzikant will provide a review of FX201,...
Oct 05, 2020 09:00 am ET
Flexion Therapeutics Announces Podium Presentation of FX301 Preclinical Data at Virtual ANESTHESIOLOGY 2020 Meeting
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the podium presentation of preclinical efficacy and pharmacokinetic (PK) data for FX301, its locally administered peripheral nerve block candidate for control of post-operative pain at the...
Oct 02, 2020 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of...
Sep 09, 2020 04:30 pm ET
Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright Virtual Healthcare Conference. The virtual fireside...
Sep 08, 2020 04:30 pm ET
Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in the second cohort of the Phase 1 dose-escalation trial evaluating the safety and tolerability of FX201, an investigational, intra-articular, IL-1Ra gene...
Sep 04, 2020 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 13,940 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of...
Sep 03, 2020 04:30 pm ET
Flexion Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference. The virtual fireside...
Aug 19, 2020 09:00 am ET
Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data Analytics at Anthem, to its Board of Directors. "We are delighted to welcome Liz to our Board of Directors as...
Aug 07, 2020 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 25,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of...
Aug 05, 2020 04:01 pm ET
Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2020. “In light of the significant challenges presented by COVID-19, we made excellent progress across all...
Jul 30, 2020 04:30 pm ET
Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020 financial results and recent business highlights after the close of the U.S. financial markets on Wednesday, August 5, 2020. About Flexion...
Jul 14, 2020 06:59 am ET
Flexion Therapeutics Announces Preliminary Second-Quarter 2020 ZILRETTA® Net Sales
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA net sales of $15.4 million for the quarter ended June 30, 2020. Demand for ZILRETTA increased month-over-month throughout the second quarter with purchases by healthcare...
Jun 16, 2020 04:30 pm ET
Flexion Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference. The...
May 21, 2020 07:30 am ET
Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at a price to the public of $9.75 per share. The gross proceeds from this offering are expected to be...
May 20, 2020 04:01 pm ET
Flexion Therapeutics Announces Proposed Public Offering of Common Stock
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. Flexion also expects to grant the underwriters a 30-day option to purchase up to an...
May 13, 2020 05:00 pm ET
Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2020 Virtual Global Healthcare Conference. The...
May 07, 2020 04:01 pm ET
Flexion Therapeutics Reports First-Quarter 2020 Financial Results and Recent Business Highlights
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2020. “We were very pleased with ZILRETTA’s trajectory earlier in the first quarter of 2020; however, in March...
May 05, 2020 09:00 am ET
Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis, at the American Society of Gene & Cell Therapy Ann
Flexion Therapeutics, Inc. (Nasdaq:FLXN) will present positive data from two studies of FX201, an investigational gene therapy for osteoarthritis (OA), at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place virtually...
May 01, 2020 09:00 am ET
Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the publication of data from two new analyses of patients treated with ZILRETTA (triamcinolone acetonide injectable suspension), including an analysis of 305 patients in the Phase 3 and Phase...
Apr 30, 2020 04:30 pm ET
Flexion Therapeutics to Report First-Quarter 2020 Financial Results on May 7, 2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 7, 2020. Flexion’s management will host a conference call at 4:30...
Apr 27, 2020 07:30 am ET
Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301, a Locally Administered Nav1.7 Inhibitor Product Candidate for Post-Operative Pain
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced new positive preclinical efficacy and pharmacokinetic (PK) data for FX301, its locally administered peripheral nerve block candidate for control of post-operative pain. Results demonstrated...
Apr 07, 2020 04:30 pm ET
Flexion Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 19th Annual Needham Virtual Healthcare Conference. The fireside chat...
Apr 03, 2020 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to seven new employees consisting of 9,265 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of...
Apr 01, 2020 07:00 am ET
Flexion Therapeutics Announces ZILRETTA® License Agreement and Provides Business Update Amid Coronavirus Pandemic
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has entered into an exclusive license agreement with HK Tainuo and Jiangsu Tainuo (a subsidiary of China Shijiazhuang Pharmaceutical Co, Ltd.) for the development and...
Mar 12, 2020 04:01 pm ET
Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $73.0 million for full-year 2019, representing more than 220% growth over 2018Analysis of Phase 3b trial investigating ZILRETTA in patients with...
Mar 11, 2020 04:30 pm ET
Flexion Therapeutics Names Melissa Layman Chief Commercial Officer
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Melissa Layman has been named Chief Commercial Officer (CCO). Ms. Layman joins Flexion with more than 25 years of commercial experience within the life science industry. Over the course...
Mar 06, 2020 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of an aggregate of 8,500 stock options and 1,500 restricted stock units. The Compensation Committee of the Board of Directors...
Mar 04, 2020 04:30 pm ET
Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2019 Financial Results on March 12, 2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2019 financial results after the close of the U.S. financial markets on Thursday, March 12, 2020. Flexion’s management will host a...
Feb 24, 2020 04:30 pm ET
Flexion Therapeutics to Present at the 41st Annual Raymond James Institutional Investors Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will be presenting at the 41st Annual Raymond James Institutional Investors Conference in Orlando, Florida. Michael Clayman, M.D., President and Chief Executive Officer, is scheduled...
Feb 07, 2020 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 13 new employees consisting of an aggregate of 40,500 stock options and 6,850 restricted stock units. The Compensation Committee of the Board of Directors approved...
Jan 13, 2020 08:30 am ET
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided a corporate update and outlined its key milestone opportunities for 2020. Dr. Simon Pimstone, Xenon’s Chief Executive Officer, said, “Xenon...
Jan 09, 2020 04:01 pm ET
Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2019 Revenue and Initial Revenue Guidance for 2020
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited revenue for the fourth-quarter and full-year ended December 31, 2019 and provided initial revenue guidance for 2020. “We are very pleased with ZILRETTA’s...
Jan 03, 2020 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of an aggregate of 17,000 stock options and 2,800 restricted stock units. The Compensation Committee of the Board of Directors...
Dec 26, 2019 04:15 pm ET
Flexion Therapeutics Announces FDA Approval of sNDA to Revise ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Product Label
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the product label for ZILRETTA (triamcinolone acetonide extended-release...
Dec 17, 2019 07:30 am ET
Flexion Therapeutics Enrolls First Patients in Phase 2 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Shoulder and Adhesive Capsulitis
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the first three patients were enrolled in a clinical trial to evaluate the efficacy of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with either...
Dec 10, 2019 09:00 am ET
Flexion Therapeutics Announces the Retirement of Neil Bodick, M.D., Ph.D., Chief Scientific Officer and Company Co-Founder
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Neil Bodick, M.D., Ph.D., Chief Scientific Officer, will retire effective January 3, 2020. Dr. Bodick co-founded Flexion in 2007 with Michael Clayman, M.D., the company’s President and...
Dec 09, 2019 09:00 am ET
Flexion Therapeutics to Host Physician Event at Orthopaedic Summit 2019 Featuring Panel of Former Professional Athletes Treated With ZILRETTA® for Osteoarthritis Knee Pain
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the speaker lineup for a “Spotlight Session” the company is hosting at the Orthopaedic Summit 2019: Evolving Techniques (OSET 2019) annual meeting in Las Vegas. Scheduled for Thursday,...
Dec 06, 2019 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of an aggregate of 25,300 stock options and 4,150 restricted stock units. The Compensation Committee of the Board of Directors...
Nov 11, 2019 07:30 am ET
Flexion Therapeutics Presents ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Efficacy Data at the AAHKS and ACR Annual Meetings
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced results from a sensitivity analysis evaluating the treatment effects of a single administration of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with...
Nov 07, 2019 04:01 pm ET
Flexion Therapeutics Reports Third-Quarter 2019 Financial Results and Recent Business Highlights
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30, 2019. “The third quarter was marked by outstanding commercial execution and growing ZILRETTA utilization...
Nov 01, 2019 04:40 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of an aggregate of 14,700 stock options and 2,500 restricted stock units. The Compensation Committee of the Board of Directors...
Oct 31, 2019 04:30 pm ET
Flexion Therapeutics to Report Third-Quarter 2019 Financial Results on November 7, 2019
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2019 financial results after the close of the U.S. financial markets on Thursday, November 7, 2019. Flexion’s management will host a conference call at...
Oct 31, 2019 07:30 am ET
Flexion Therapeutics Announces FDA Clearance of the Investigational New Drug Application for FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced clearance of the company's Investigational New Drug (IND) application for FX201 in knee osteoarthritis (OA), a painful, chronic and progressive disease that affects more than 15 million...
Oct 14, 2019 07:00 am ET
Flexion Therapeutics Announces Extended FDA Review of Supplemental New Drug Application for ZILRETTA®
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has informed the company it needs additional time to complete the review of the supplemental New Drug Application (sNDA) for ZILRETTA...
Oct 04, 2019 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 13 new employees consisting of an aggregate of 80,550 stock options and 13,425 restricted stock units. The Compensation Committee of the Board of Directors...
Oct 02, 2019 09:00 am ET
Former NY Yankees Outfielder Chris Dickerson Teams Up With Flexion Therapeutics to Raise Awareness of Impact of Osteoarthritis (OA)
Flexion Therapeutics (Nasdaq:FLXN) is teaming up with Chris Dickerson, a former New York Yankees outfielder and member of the 2011 and 2012 playoff teams, to raise awareness of the impact of osteoarthritis (OA). Introduced at the start of...
Sep 30, 2019 09:04 am ET
Flexion Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the annual Cell & Gene Meeting on the Mesa in Carlsbad, California. Dr. Muzikant will provide an...
Sep 23, 2019 09:00 am ET
Flexion Therapeutics Sponsors a Memorial to the Victims of the Opioid Crisis to Raise Awareness of the Tragic Consequences of the Opioid Epidemic Across the U.S.
Flexion Therapeutics, Inc. (Nasdaq:FLXN), a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA),...
Sep 09, 2019 04:01 pm ET
Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain
Flexion Therapeutics, Inc. (Nasdaq:FLXN) and Xenon Pharmaceuticals Inc. (Nasdaq:XENE) today announced that the companies have entered into a definitive agreement that provides Flexion with the global rights to develop and commercialize XEN402, a...
Sep 06, 2019 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to nine new employees consisting of an aggregate of 25,900 stock options and 4,350 restricted stock units. The Compensation Committee of the Board of Directors...
Aug 28, 2019 04:30 pm ET
Flexion Therapeutics to Present at the Wells Fargo Securities 2019 Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo Securities 2019 Healthcare Conference in Boston,...
Aug 06, 2019 04:01 pm ET
Flexion Therapeutics Reports Second-Quarter 2019 Financial Results and Recent Business Highlights
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2019. “The second quarter was marked by excellent progress across all areas of our business, most notably,...
Aug 02, 2019 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 11 new employees consisting of an aggregate of 68,650 stock options and 11,525 restricted stock units. The Compensation Committee of the Board of Directors...
Jul 30, 2019 04:30 pm ET
Flexion Therapeutics to Report Second-Quarter 2019 Financial Results on August 6, 2019
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2019 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2019. Flexion’s management will host a conference call at...
Jul 15, 2019 07:30 am ET
Flexion Therapeutics Presents New Data Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Patients with Advanced Knee OA
An analysis of clinical trial data indicates ZILRETTA reduced pain with similar improvements observed after each of two injections in patients with knee OA classified as Kellgren-Lawrence (KL) Grades 2-4 >- Flexion Therapeutics, Inc. (Nasdaq:FLXN)...
Jul 03, 2019 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to ten new employees consisting of an aggregate of 29,050 stock options and 5,350 restricted stock units. The Compensation Committee of the Board of Directors...
Jun 20, 2019 09:00 am ET
Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Third Consecutive Year
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named one of Boston Business Journal’s “Best Places to Work” for the third consecutive year. Flexion was the only Boston-area biopharmaceutical company recognized in the...
Jun 18, 2019 04:30 pm ET
Flexion Therapeutics to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the BMO Capital Markets 2019 Prescriptions for Success Healthcare...
Jun 07, 2019 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 10 new employees consisting of an aggregate of 25,250 stock options and 4,350 restricted stock units. The Compensation Committee of the Board of Directors approved...
Jun 05, 2019 08:30 am ET
Flexion Therapeutics Announces Issuance of New U.S. Patent Covering FX201 a Gene Therapy Product Candidate for the Treatment of Osteoarthritis
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent number 10,301,645 for FX201, the company's gene therapy product candidate. The patent covers the composition of matter and...
May 14, 2019 04:30 pm ET
Flexion Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2019 RBC Capital Markets Global Healthcare Conference in New York...
May 10, 2019 07:30 am ET
Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that a pooled analysis of data from three Phase 2/3 randomized clinical trials on the use of rescue medications with ZILRETTA (triamcinolone acetonide extended-release injectable suspension)...
May 08, 2019 04:01 pm ET
Flexion Therapeutics Reports First-Quarter 2019 Financial Results and Recent Business Highlights
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2019. “Flexion delivered solid ZILRETTA sales performance in the first quarter of 2019,” said Michael...
May 03, 2019 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of an aggregate of 7,600 stock options and 1,250 restricted stock units. The Compensation Committee of the Board of Directors approved...
May 02, 2019 09:00 am ET
Flexion Therapeutics Announces Upcoming Presentations at the 2019 Osteoarthritis Research Society International (OARSI) World Congress
Flexion Therapeutics, Inc. (Nasdaq:FLXN) will present data from three recent studies at the Osteoarthritis Research Society International (OARSI) World Congress taking place May 2-5, 2019 in Toronto, Canada. “As a company focused on advancing...
May 01, 2019 04:30 pm ET
Flexion Therapeutics to Report First-Quarter 2019 Financial Results on May 8, 2019
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2019 financial results after the close of the U.S. financial markets on Wednesday, May 8, 2019. Flexion’s management will host a conference call at 4:30...
Apr 24, 2019 04:30 pm ET
Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
Post-hoc analysis published in Advances in Therapy indicated patients with unilateral knee osteoarthritis experienced significant and durable reductions in pain with ZILRETTA vs. immediate-release triamcinolone acetonide Patients in ZILRETTA arm...
Apr 08, 2019 08:30 am ET
Report: Exploring Fundamental Drivers Behind Zscaler, Golden Star Resources, Flexion Therapeutics, SP Plus, Insys Therapeutics, and OMNOVA Solutions — New Horizons, Emerging Trends, and Upcoming Devel
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Zscaler, Inc. (NASDAQ:ZS), Golden Star Resources, Ltd (NYSE:GSS), Flexion...
Apr 05, 2019 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of an aggregate of 61,000 stock options and 26,900 restricted stock units. The Compensation Committee of the Board of Directors...
Apr 03, 2019 04:30 pm ET
Flexion Therapeutics to Present at the 18th Annual Needham & Company Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 18th Annual Needham & Company Healthcare Conference in New York...
Apr 02, 2019 07:30 am ET
Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal Drugs
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced an independent evaluation of clinical data for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), conducted by Adis Drug Review, was published in the journal Drugs...
Apr 01, 2019 09:00 am ET
Flexion Therapeutics Announces Kerry Wentworth, Chief Regulatory Officer, Appointed to Massachusetts Biotechnology Council Board
Flexion Therapeutics today announced that Kerry Wentworth, Chief Regulatory Officer, has been appointed to the Massachusetts Biotechnology Council (MassBio) Board of Directors. “It is a pleasure to welcome Kerry to our Board of Directors,”...
Mar 04, 2019 04:30 pm ET
Flexion Therapeutics to Present at the Cowen 39th Annual Health Care Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Cowen 39th Annual Health Care Conference in Boston, Massachusetts. Dr. Clayman is scheduled to present...
Mar 01, 2019 04:45 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to five new employees for an aggregate of 19,250 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an...
Feb 28, 2019 04:01 pm ET
Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2018 Financial Results
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter and the year ended December 31, 2018. “In 2018, we made strong progress establishing ZILRETTA in the market, laying a...
Feb 26, 2019 04:30 pm ET
Flexion Therapeutics to Present at the 40th Annual Raymond James Institutional Investors Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will be presenting at the 40th Annual Raymond James Institutional Investors Conference in Orlando, Florida. Michael Clayman, M.D., President and Chief Executive Officer, is scheduled...
Feb 21, 2019 04:30 pm ET
Flexion Therapeutics Announces New In Vitro Data Showing Protective Effects of Triamcinolone Acetonide on Cartilage
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced results from a preclinical study which showed that triamcinolone acetonide (TA) had protective effects on inflamed and/or injured cartilage. Led by Professor Alan Grodzinsky, Sc.D., Director...
Feb 20, 2019 04:30 pm ET
Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2018 Financial Results on February 28, 2019
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2018 financial results after the close of the U.S. financial markets on Thursday, February 28, 2019. Flexion’s management will host a...
Feb 11, 2019 04:05 pm ET
Flexion Therapeutics Announces Publication of Data from Repeat Administration Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Rheumatology and Therapy
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the results from an open-label Phase 3b clinical trial evaluating the safety and exploratory efficacy of repeat administration of ZILRETTA (triamcinolone acetonide extended-release...
Feb 08, 2019 09:00 am ET
Flexion Therapeutics to Ring Nasdaq Stock Market Opening Bell on Tuesday, February 12
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has been invited to ring the Nasdaq opening bell on Tuesday, February 12, 2019 to commemorate the fifth anniversary of the company’s initial public offering (IPO). Michael Clayman,...
Feb 01, 2019 05:00 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to 14 new employees for an aggregate of 51,000 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an...
Jan 30, 2019 07:20 am ET
Consolidated Research: 2019 Summary Expectations for Telephone and Data, EMCOR Group, Chart Industries, Alarm, Flexion Therapeutics, and Social Reality — Fundamental Analysis, Key Performance Indicati
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Telephone and Data Systems, Inc. (NYSE:TDS), EMCOR Group, Inc. (NYSE:EME),...
Jan 22, 2019 04:30 pm ET
Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Christina Willwerth has been named Chief Strategy Officer. Ms. Willwerth joined Flexion in June 2009, and she most recently served as the company’s Senior Vice President of Program...
Jan 04, 2019 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an aggregate of 53,700 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an...
Jan 03, 2019 04:01 pm ET
Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2018 Revenue and Initial Revenue Guidance for 2019
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited revenue for the fourth-quarter and full-year ended December 31, 2018 and provided initial revenue guidance for 2019. “2018 was a foundational year for ZILRETTA®,...
Jan 02, 2019 04:30 pm ET
Flexion Therapeutics Enrolls First Patient in Phase 3 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Hip and Reports Results from SHIP Study
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that, on December 26, 2018, the first patient was enrolled in a Phase 3 clinical trial to evaluate the safety and efficacy of ZILRETTA (triamcinolone acetonide extended-release injectable...
Dec 20, 2018 04:00 pm ET
Flexion Therapeutics to Report Preliminary Unaudited 2018 Revenue and Provide 2019 Revenue Guidance on January 3, 2019
Flexion Therapeutics, Inc. (Nasdaq:FLXN) will announce preliminary unaudited revenue for the fourth-quarter and full-year 2018 and provide revenue guidance for 2019 on Thursday, January 3, 2019, after market close. The company will hold a...
Dec 17, 2018 04:30 pm ET
Flexion Therapeutics Submits Supplemental New Drug Application (sNDA) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced it submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to revise the product label for ZILRETTA (triamcinolone acetonide extended-release...
Dec 04, 2018 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to five new employees for an aggregate of 24,150 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an...
Nov 27, 2018 08:45 am ET
New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Phibro Animal Health Corporation (NASDAQ:PAHC), RadNet, Inc....
Nov 16, 2018 09:22 am ET
Flexion Therapeutics Named Top Place to Work for Second Consecutive Year by The Boston Globe 
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named one of the Top Places to Work in Massachusetts for the second consecutive year. The rankings are based on the results from an annual employee survey conducted by The...
Nov 07, 2018 04:01 pm ET
Flexion Therapeutics Reports Third-Quarter 2018 Financial Results and Recent Business Highlights
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30, 2018. “In the third quarter, we saw growing demand for ZILRETTA as evidenced by an 84% increase in sales...
Nov 05, 2018 06:30 am ET
Flexion Therapeutics Announces Product-Specific J Code (J3304) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Effective January 1, 2019
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a product-specific J code for ZILRETTA (triamcinolone acetonide extended-release injectable suspension). Under the...
Oct 31, 2018 07:30 am ET
Flexion Therapeutics to Report Third-Quarter 2018 Financial Results on November 7, 2018
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2018 financial results after the close of the U.S. financial markets on Wednesday, November 7, 2018. Flexion’s management will host a conference call at...
Oct 22, 2018 07:30 am ET
Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Bilateral Knee OA at 2018 ACR Annual Meeting
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today will present the results from a Phase 2 clinical trial evaluating the pharmacokinetics (PK) and safety of concurrent administration of ZILRETTA (triamcinolone acetonide extended-release injectable...
Oct 16, 2018 08:45 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Iamgold, Mazor Robotics, Flexion Therapeutics, Hemisphere Media Group, Criteo S.A, and EP Energy — New Research Emphasizes Economic
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Iamgold Corporation (NYSE:IAG), Mazor Robotics Ltd. (NASDAQ:MZOR),...
Oct 05, 2018 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to three new employees for an aggregate of 20,600 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an...
Sep 10, 2018 09:00 am ET
Flexion Therapeutics Announces Publication of Phase 2 Diabetes Data in September Issue of Rheumatology
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that data from a Phase 2 study of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) evaluating blood glucose levels in patients with osteoarthritis knee pain and Type...
Sep 07, 2018 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an aggregate of 10,500 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an...
Aug 28, 2018 04:30 pm ET
Flexion Therapeutics to Present at the 2018 Wells Fargo Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will present at the 13th Annual Wells Fargo Securities Healthcare Conference taking place at the Westin Copley Place in Boston, Massachusetts. Michael Clayman, M.D., President and...
Aug 20, 2018 05:23 pm ET
Flexion Therapeutics Announces Presentation of Phase 3 Data at Military Health System Research Symposium
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today presented data from a previously reported post-hoc analysis of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in an oral session at the Military Health System Research...
Aug 17, 2018 08:00 am ET
Report: Developing Opportunities within Adesto Technologies, BLACKLINE INC, Altice, Flexion Therapeutics, EZCORP, and CorVel — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Adesto Technologies Corporation (NASDAQ:IOTS), BLACKLINE INC (NASDAQ:BL),...
Aug 07, 2018 04:01 pm ET
Flexion Therapeutics Reports Second-Quarter 2018 Financial Results and Recent Business Highlights
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2018. “We saw strong growth in demand for ZILRETTA in the second quarter, as evidenced by a 73% increase in...
Aug 03, 2018 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to six new employees for an aggregate of 14,800 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an...
Jul 30, 2018 04:30 pm ET
Flexion Therapeutics to Report Second-Quarter 2018 Financial Results on August 7, 2018
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2018 financial results after the close of the U.S. financial markets on Tuesday, August 7, 2018. Flexion’s management will host a conference call at...
Jul 03, 2018 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to nine new employees for an aggregate of 30,700 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an...
Jun 21, 2018 09:00 am ET
Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Second Year in a Row
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named as one of the Boston Business Journal’s “Best Places to Work” for the second year in a row. Flexion was ranked among the top 15 companies in the medium business...
Jun 13, 2018 09:00 am ET
Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
DURHAM, N.C., June 13, 2018 /PRNewswire/ -- Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announced the expanded deployment of its Extended Workbench laboratory services program to support the ongoing manufacturing and development of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension). ZILRETTA is the first U.S. Food and Drug Administration (FDA) approved product from Flexion Therapeutics, Inc., a Massachusetts-based biopharmaceutical company focused on the development a
Jun 01, 2018 05:13 pm ET
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to eight new employees for an aggregate of 50,000 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an...
May 29, 2018 08:10 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3 Energy Partners LP, Flexion Therapeutics, and Enanta Pharmaceuticals — N
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Assembly Biosciences, Inc. (NASDAQ:ASMB), MGP Ingredients, Inc....
May 08, 2018 04:01 pm ET
Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2018. “The first quarter of 2018 was marked by encouraging sales of ZILRETTA (triamcinolone acetonide...
May 07, 2018 07:30 am ET
Flexion Therapeutics Names David Arkowitz as Chief Financial Officer
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that David Arkowitz has been named Chief Financial Officer (CFO). Mr. Arkowitz brings more than 25 years of finance and operations leadership experience in the life sciences and biotechnology...
May 04, 2018 07:30 am ET
Flexion Therapeutics Announces ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Recommended for Unique J Code by CMS
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the Centers for Medicare and Medicaid Services (CMS) has included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) on its list of products that have been recommended...
May 03, 2018 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to seven new employees for an aggregate of 38,300 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an...
Apr 30, 2018 04:30 pm ET
Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018
BURLINGTON, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2018 financial results after the close of the U.S. financial markets on Tuesday, May 8, 2018. Flexion’s management will host...
Apr 29, 2018 09:00 am ET
Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society International World Congress
Results from preclinical osteoarthritis (OA) models demonstrate relief of pain, functional improvement and suggest disease-modifying efficacy following a single intra-articular injection
Apr 26, 2018 07:30 am ET
Flexion Therapeutics Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at Osteoarthritis Resea
BURLINGTON, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced updated interim findings from its ongoing Phase 3b, open-label study to evaluate the overall safety and general tolerability of repeat administration of ZILRETTA (triamcinolone acetonide...
Apr 24, 2018 04:30 pm ET
Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at the Academy of Managed Care Pharmacy Annual Meeting 2018
BURLINGTON, Mass., April 24, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) will present positive clinical data from a post-hoc analysis of patients with unilateral knee osteoarthritis (OA) pain from its Phase 3 trial. The results indicated that...
Apr 18, 2018 04:20 pm ET
Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint Surgery
BURLINGTON, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the key results from the previously completed pivotal Phase 3 study evaluating ZILRETTA (triamcinolone acetonide extended-release injectable suspension) have been published in the...
Apr 06, 2018 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BURLINGTON, Mass., April 06, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an aggregate of 12,300 shares of common stock. The Compensation Committee of the...
Apr 05, 2018 07:55 am ET
Detailed Research: Economic Perspectives on The Habit Restaurants, MUELLER WATER PRODUCTS, The Carlyle Group, Flexion Therapeutics, Hexcel, and Adesto Technologies — What Drives Growth in Today's Comp
NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Habit Restaurants, Inc. (NASDAQ:HABT), MUELLER...
Mar 19, 2018 09:00 am ET
Flexion Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference
BURLINGTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in a fireside chat at...
Mar 08, 2018 04:01 pm ET
Flexion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
BURLINGTON, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the fourth quarter and the full year ended December 31, 2017.
Mar 07, 2018 09:00 am ET
Flexion Therapeutics to Present at the Cowen 38th Annual Health Care Conference
BURLINGTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) will be presenting at the Cowen 38th Annual Health Care Conference in Boston, Massachusetts. Michael Clayman, M.D., President and Chief Executive Officer, is scheduled to present...
Mar 06, 2018 07:30 am ET
Flexion Therapeutics Presents Clinical Data at AAOS 2018 Annual Meeting and the American Pain Society Annual Scientific Meeting
BURLINGTON, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) will present positive data from three studies of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), also referred to as TA-ER/FX006, in patients with osteoarthritis (OA) knee pain. Two data...
Mar 02, 2018 04:30 pm ET
Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BURLINGTON, Mass., March 02, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to two new employees for an aggregate of 4,000 shares of common stock. The Compensation Committee of the...
Feb 28, 2018 09:00 am ET
Flexion Therapeutics to Present at the 39th Annual Raymond James Institutional Investors Conference
BURLINGTON, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Raymond James 39th Annual Institutional Investors Conference in Orlando, Florida. Dr....
Feb 26, 2018 04:30 pm ET
Flexion Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 8, 2018
BURLINGTON, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth quarter and full year 2017 financial results after the close of the U.S. financial markets on Thursday, March 8, 2018....
Feb 14, 2018 04:30 pm ET
Flexion Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
BURLINGTON, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in a fireside chat at...
Feb 08, 2018 07:55 am ET
New Research: Key Drivers of Growth for Radian Group, Flexion Therapeutics, Andeavor, Haverty Furniture Companies, Ares Capital, and Sempra Energy — Factors of Influence, Major Initiatives and Sustain
NEW YORK, Feb. 08, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Radian Group Inc. (NYSE:RDN), Flexion Therapeutics,...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.